FDA Expands Use of Approved Breast Cancer Drug

January 29, 2020

U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

Dual HER2-blockade regimen boosts overall survival in refractory metastatic breast ca

January 21, 2021

By Caroline Helwick, Oncology NEWS International

SAN ANTONIO—The targeted combination of lapatinib (Tykerb) plus trastuzumab (Herceptin) led to a median overall survival of 14 months in women with refractory metastatic breast cancer, according to an updated analysis of the phase III EGF104900 trial

Women with breast cancer may benefit from autologous stem cell transplantation

January 12, 2021

By Health & Medicine

Compared to conventional chemotherapy, autologous stem cell transplantation can extend “event-free survival” for breast cancer patients. Clinical trials provide proof of this for breast cancer with and without distant metastases.

Lombardi researchers find investigational agent reduces tumor resistance to breast cancer therapy

January 5, 2021

By Karen Mallet, Georgetown University Medical Center

Researchers find out why estrogen-positive tumors stop responding to commonly used drugs, pointing a way to new therapies
Washington, DC – Researchers at Georgetown Lombardi Comprehensive Cancer Center have found a way to cleverly override signals that tell breast cancer cells to keep surviving in the face of anticancer treatment. The investigational agent they used renews the sensitivity of these breast cancer cells to treatment by fulvestrant (Faslodex®) which had stopped working.

Tumours can re-seed themselves

January 3, 2021

By The International News

Tumours cannot only spread through the body by sending out tiny cells called seeds, but they can re-seed themselves, researchers said in a report that may help explain why tumours grow back even after they are removed.